The personalized vaccine, known scientifically as intismeran autogene, when paired with Merck’s blockbuster immunotherapy Keytruda, demonstrated a significant clinical benefit. According to the full data set, the combination therapy reduced the risk of recurrence or death in certain melanoma patients by 42% compared with the administration of Keytruda alone.
Furthermore, the data showed that the innovative shot, when used alongside Keytruda, successfully reduced the risk of cancer spreading to distant parts of the body, or death, by 38% compared with the immunotherapy alone. Highlighting the longevity of the treatment’s impact, the companies reported that about 82% of patients who received the personalized cancer vaccine alongside Keytruda were alive and without their melanoma returning two years after receiving the shot. This compared favorably with 70% of those patients who received Keytruda alone.
Medical professionals immediately recognized the weight of the findings. "This is a huge development for our patients," said Dr. Hussein Tawbi, a melanoma expert and trial investigator at the University of Texas MD Anderson Cancer Center, reflecting on the results. He added that the added benefit of the vaccine also comes with much milder toxicity—such as manageable side effects like injection-site pain—when compared to other traditional and aggressive cancer treatments.
The detailed phase 3 trial results were scheduled to be presented formally at the upcoming European Society for Medical Oncology conference over the weekend. The data reinforces confidence in a novel approach to oncology that seeks to harness the body’s own immune system to fight specific, patient-unique cellular threats.
"Whenever you put a therapy on top of something that works really well, like Keytruda, sometimes it’s harder to show additional benefit. We have no problems of showing additional benefit here," Dr. Dean Li, president of Merck Research Laboratories, said in an interview ahead of the results.
The therapeutic benefit appeared even more pronounced after the completion of the six-month vaccine regimen. A separate analysis revealed a striking 58% reduction in the risk of recurrence or death for those who finished the protocol. However, company executives noted that it remains too early to determine definitively whether the combination treatment helps patients live longer overall, as long-term overall survival data continues to mature.
Several financial analysts acknowledged that investors had built up exceptionally elevated expectations ahead of the release, creating a volatile backdrop for the stock price despite the fundamentally positive data.
"We assert this relative reduction in recurrence/death is clinically meaningful," BMO Capital Markets analyst Evan Seigerman wrote in a research note published on Thursday following the leak. "Such a stock reaction likely reflects inflated expectations into the full data release, rather than a true indictment on the efficacy of the combo therapy."
Oncologists and market investors alike view the targeted vaccine as a potential watershed moment in oncology, carrying the promise of future applications across a wide array of other cancer types. Currently, Merck and Moderna are actively studying the personalized vaccine in several rigorous clinical trials targeting other challenging tumors, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
Nevertheless, Merck’s Dr. Li acknowledged that the companies still have substantial work ahead of them to conclusively demonstrate that the product can achieve broad efficacy across diverse tumor types.
"I can dream of creating a log cabin, but we got some wood chops, and we’ve just knocked down one tree," Li remarked, using a metaphor to describe the early stage of their oncology ambitions. "Knocking one tree does not give you a cabin or a village."
For now, however, the vaccine is moving steadily closer to potentially entering the commercial market for the very first time and directly reaching melanoma patients in need. In an interview conducted ahead of the results, Moderna CEO Stéphane Bancel stated that the company is actively finalizing a regulatory filing with health authorities to secure full approval for the drug next year.
"It’s a very, very happy moment for the field, for patients," Bancel said.
The mechanism behind the shot is fundamentally distinct from conventional therapies. It is meticulously designed to target the specific mutations unique to each individual patient’s tumor, moving away from a traditional one-size-fits-all medical approach. The core concept is to train the patient’s immune system to recognize and ruthlessly destroy those unique cancer markers, subsequently pairing that targeted cellular response with Keytruda, which helps the body’s immune cells attack the malignancy more effectively.
For Moderna, the vaccine could also offer a critical additional commercial product in its expanding portfolio, providing diversification following its rollout of vaccines for Covid-19, the seasonal flu, and respiratory syncytial virus.
Echoing similar sentiments regarding the market reaction, analysts at UBS noted in a research note on Thursday that "this is overall a strong data set" that instills greater confidence in upcoming clinical studies evaluating the vaccine in kidney and bladder cancers. They reiterated that the sharp negative stock movement was likely driven more by massive, unrealistic short-term expectations than by any genuine disappointment within the clinical data.
Against the backdrop of those very high expectations, Moderna shares had nevertheless experienced a dramatic rally, spiking more than 530% year-to-date as of Thursday afternoon trading.
Meanwhile, shares of Merck, a significantly larger pharmaceutical enterprise, fell by about 1% on Thursday, reflecting a more muted movement for a company with a broad and established revenue base. Merck’s stock has climbed nearly 41% over the course of the year.
Because the vaccine is entirely personalized to the individual’s genetic profile, the intricate manufacturing process is complex and currently takes about six weeks to complete. However, Merck CEO Robert Davis told CNBC last week that the company firmly believes it can shorten that manufacturing timeline in the future, a development that would potentially allow the breakthrough shot to reach a significantly larger population of patients much more quickly.
